Novel β-amyloid PET Imaging Study of [18F]92 in Patients with Cognitive Decline

• DOI: 10.1021/acsomega.4c03412
• Publication Date: 2024-08-01T06:22:43Z
• Authors: Ming Ni; Xingxing Zhu; Kaixuan Wang; Wenliang Guo; Qin Shi; Yuying Li; Mengchao Cui; Qiang Xie
• Keywords: Radiosynthesis; Standardized uptake value; PET Imaging

[18F]-4-((E)-(((E)-4-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)benzylidene)-hydrazono)methyl)-N-methylaniline ([18F]92) is a novel positron emission tomography (PET) tracer previously reported to exhibit high binding affinity aggregated β-amyloid (Aβ). This study aims report fully automated radiosynthesis procedure for [18F]92, explore its radioactive distribution in the brains of healthy subjects, and investigate potential application value early diagnosis Alzheimer's disease (AD). The [18F]92 was performed on AllinOne module. Thirty one participants were recruited this study. Dynamic PET imaging conducted over 0–90 min period assess time–activity curves (TAC) standardized uptake ratio (SUVR) cognitively normal (CN) subjects. All visually classified as either positive (+) or negative (−). Semiquantitative analyses by calculating SUVRs different regions interest. Furthermore, analyzed relationships between global SUVR plasma AD biomarkers, including Aβ42, Aβ40, P-tau181, T-tau. completed within 50 min, yielding radiochemical purity greater than 95% yield 36 ± 3% (nondecay-corrected). Among participants, 15 estimated Aβ (−) 16 (+). TACs indicated that rapidly crossed blood–brain barrier 10 followed rapid decrease, which then slowed down last 50–90 min. revealed values stabilized around 60–70 after injection reached an equilibrium 70 90 primarily cerebral cortex. significantly higher those individuals In addition, Aβ42 Aβ42/Aβ40 exhibited correlations with SUVR, while P-tau181 P-tau181/T-tau displayed SUVR. exhibits excellent pharmacokinetic properties human brain can be synthesized automatically large scale. promising reliable radiotracer estimating pathology accumulation, providing valuable assistance guiding clinical trials therapeutic drugs.